Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan in Primary FSGS
NCT03493685Phase 3Completed
- Sponsor
- Travere Therapeutics
- Start
- Apr 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of sparsentan in focal segmental glomerulosclerosis (FSGS), sponsored by Travere Therapeutics. Started Apr 2018; status: completed.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03493685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493685.